GSK plc
Financials
Valuation Metrics
GSK plc's Market Cap is $100.79B. At end of 2025 it was $99.07B. Ranked #157 of 3,121 in US market (top 5%), #110 of 1,658 on NYSE (top 7%), #14 of 266 in Pharmaceuticals, Biotechnology & Life Sciences (top 5%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $100.79B | US#157/3,121 Sec#14/266 |
| Revenue | $43.78B | US#145/3,121 Sec#11/266 |
| Net Income | $6.36B | US#125/3,121 Sec#8/266 |
| Total Assets | $82.64B | US#219/3,121 Sec#13/266 |
| Net Assets | $23.62B | US#209/3,121 Sec#11/266 |
| Employees | 66,841 | US#194/3,121 Sec#8/266 |
| Value | ||
| P/E | 15.86x | US#846/3,121 Sec#25/266 |
| P/B | 4.27x | US#2,097/3,121 Sec#127/266 |
| PEG | 0.39x | US#527/3,121 Sec#18/266 |
| P/S | 2.30x | US#1,439/3,121 Sec#34/266 |
| EV/EBITDA | 8.45x | US#589/3,121 Sec#16/266 |
| FCF Yield | 9.13% | US#722/3,121 Sec#23/266 |
| Profitability | ||
| ROE | 26.91% | US#356/3,121 Sec#20/266 |
| ROA | 7.69% | US#692/3,121 Sec#42/266 |
| Op. Margin | 20.70% | US#873/3,121 Sec#38/266 |
| Revenue Growth | 4.97% | US#1,816/3,121 Sec#116/266 |
| Earnings Growth | 40.84% | US#580/3,121 Sec#24/266 |
| Financial Health | ||
| Debt Ratio | 252.54% | US#1,984/3,121 Sec#207/266 |
| Total Debt | $24.41B | US#193/3,121 Sec#13/266 |
| FCF | $9.20B | US#93/3,121 Sec#11/266 |
| Cash | $4.16B | US#236/3,121 Sec#13/266 |
| Current Ratio | 0.82x | US#2,487/3,121 Sec#265/266 |
| Net Debt/EBITDA | 1.41x | US#1,125/3,121 Sec#51/266 |
| Dividend | ||
| Div. Yield | 3.80% | US#464/3,121 Sec#7/266 |
| Div. Growth | 2.61% | US#1,015/3,121 Sec#17/266 |
| Performance | ||
| 1Y Return | 24.63% | US#996/3,121 Sec#145/266 |
| 1M Return | -5.02% | US#962/3,121 Sec#93/266 |
| From 52W High | -18.60% | US#1,301/3,121 Sec#89/266 |
| 1Y MDD | -21.35% | US#808/3,121 Sec#34/266 |
| Trading | ||
| Volume | 4,059,344 shares | US#618/3,121 Sec#57/266 |
| Trading Value | $203M | US#619/3,121 Sec#39/266 |
| Per Share | ||
| EPS | $3.17 | US#1,025/3,121 Sec#28/266 |
| BPS | $11.77 | US#1,733/3,121 Sec#63/266 |
Company Info
GSK plc, a global pharmaceutical entity founded in 1715 and headquartered in Brentford, United Kingdom, dedicates its efforts to the research, development, and manufacturing of a wide array of medical solutions. Until May 2022, the company was known as GlaxoSmithKline plc. Its primary objective is to prevent and treat illnesses by producing both vaccines and a comprehensive range of specialty and general medicines for markets across the United Kingdom, the United States, and internationally. The company's operations are organized into two key divisions: Commercial Operations and Total R&D. Its extensive vaccine portfolio includes immunizations against shingles, meningitis, respiratory syncytial virus (RSV), seasonal and pandemic influenza, and polio. Beyond preventative care, GSK provides diverse therapeutic products covering critical areas such as HIV, oncology, respiratory and immunology conditions, and other specialized medical fields. This also encompasses inhaled treatments for chronic respiratory ailments like asthma and chronic obstructive pulmonary disease (COPD), along with antibiotics for various infections. Innovation at GSK is frequently driven by strategic partnerships. Notable collaborations include an agreement with CureVac to advance mRNA-based influenza vaccines, and alliances with Wave Life Sciences and Elsie Biotechnologies focused on developing oligonucleotide platforms. Furthermore, GSK has established two distinct strategic collaborations with Relation to progress therapeutics for fibrotic diseases and osteoarthritis. The company is also engaged in a multi-target strategic alliance aimed at developing pioneering treatments for individuals suffering from Parkinson's disease, and a partnership with Flagship Pioneering to identify novel medicines and vaccines.